Astra Cuts $3.5 Billion Target for Brilinta After Trial Setback

  • U.K. drugmaker’s 2023 revenue target is now ‘unrealistic’
  • Euclid trial is latest blow to sales ambitions for franchise

AstraZeneca Plc’s ambitions for its heart pill Brilinta have been thwarted after the medicine didn’t beat an older blood-thinner in a key study, the second such failure this year.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.